Kuria Therapeutics

Powering Sight

[Kuria Therapeutics @KuriaTx]

We're delighted to share our latest news about the closing of our initial financing round - great progress, and stay tuned for more to come!

[ASCRS @ASCRStweets]

Victory for cataract surgeons and their patients, a great way to close out this Cataract Awareness Month! Read about ASCRS advocacy efforts that led to Aetna dropping its prior authorization policy https://t.co/SiIBCkwVwJ #ASCRScatarACTION #CataractAwarenessMonth

[日経バイオテク＠無料メルマガ配信中 @nikkeibiotech]

武田薬品発のスコヒアファーマが、Nrf2活性化薬SCO-116の全世界の商業化権利を、米Kuria Therapeutics社に導出する契約を結んだと発表。ユビキチン・プロテアソーム系の蛋白質分解を抑えること��、細胞保護効果を示す薬剤です。https://t.co/3izz8hJcTX

[Kuria Therapeutics @KuriaTx]

Our #firsttweet and it’s a big one – we’ve in-licensed our initial development program, a novel #Nrf2 activator from @SCOHIAPHARMA ! Excited to share more of our plans and progress in #ophthalmology and #dermatology in the future!